Performance of two rapid antigen tests against SARS-CoV-2 in neighborhoods of socioeconomic vulnerability from a middle-income country
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0298579 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Diana Zeballos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Sensitivity and Specificity, COVID-19 Serological Testing. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Unitaid.
Abstract (Originalsprache)
Background
As new and improved antigen-detecting rapid diagnostic tests for SARS-CoV-2 infection (Ag-RDT) continue to be developed, assessing their diagnostic performance is necessary to increase test options with accurate and rapid diagnostic capacity especially in resource-constrained settings. This study aimed to assess the performance of two Ag-RDTs in a population-based study.
Methods
We conducted a diagnostic accuracy study in neighborhoods with high socioeconomic vulnerability in Salvador-Brazil, including individuals aged ≥12 years old who attended primary health services, between July and December 2022, with COVID-19 symptoms or who had been in contact with a confirmed case. Two Ag-RDTs were compared in parallel using reverse transcription polymerase chain reaction (RT-PCR) as reference standard, the Panbio TM COVID-19 Ag test (Abbott®) and Immuno-Rapid COVID-19 Ag (WAMA Diagnostic®). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) were calculated.
Results
For the Abbott test the sensitivity was 52.7% (95% CI: 44.3% - 61.0%), specificity 100% (95% CI: 98.7% - 100%), PPV 100% (95% CI: 95.4% - 100%) and NPV 80.4% (95% CI: 75.9% - 84.4%). For the WAMA test, the sensitivity was 53.4% (95% CI: 45.0% - 61.6%), specificity 100% (95% CI: 98.7% - 100%), PPV 100% (95% CI: 95.4% - 100%) and NPV 80.7% (95% CI: 76.2% - 84.6%). Sensitivity for the group with Cycle Threshold (CT)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
- Departamento de Ciências da Vida, Universidade do Estado da Bahia, Salvador, Bahia, Brazil.
- Departamento de Estatística, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
- Laboratório de Virologia Molecular, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
ORCID-Profile: Diana Zeballos, Carina Carvalho Dos Santos, Joice Neves Reis, Thiago S Torres
Förderung
- NIAID NIH HHS
- Unitaid
Zitieren
APA
Zeballos, D., Magno, L., Aranha Rossi, T., Soares, F., Pinto Junior, J. A., Ferreira, O., Carvalho Dos Santos, C., Reis, J. N., Torres, T. S., Veloso, V. G., & Dourado, I. (2024). Performance of two rapid antigen tests against SARS-CoV-2 in neighborhoods of socioeconomic vulnerability from a middle-income country. PLOS ONE. https://doi.org/10.1371/journal.pone.0298579
Vancouver
Zeballos D, Magno L, Aranha Rossi T, Soares F, Pinto Junior JA, Ferreira O, et al. Performance of two rapid antigen tests against SARS-CoV-2 in neighborhoods of socioeconomic vulnerability from a middle-income country. PLOS ONE. 2024. doi:10.1371/journal.pone.0298579
BibTeX
@article{Zeballos2024,
author = {Zeballos, Diana and Magno, Laio and Aranha Rossi, Thais and Soares, Fabiane and Pinto Junior, Jony Arrais and Ferreira, Orlando and Carvalho Dos Santos, Carina and Reis, Joice Neves and Torres, Thiago S and Veloso, Valdilea G and Dourado, Inês},
title = {Performance of two rapid antigen tests against SARS-CoV-2 in neighborhoods of socioeconomic vulnerability from a middle-income country},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0298579}
}
EUVIMED